Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
List view / Grid view
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
Researchers say that inhibiting NLRP3 with Dapansutrile could be an effective strategy to prevent melanoma tumour growth.
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
A team has shown that tilorone, quinacrine and pyronaridine are effective at inhibiting the replication of SARS-CoV-2 in vitro.
A year on from discovering COVID-19 we are starting to understand why some people suffer more severely after infection. Sadya Arnett discusses recent research into the interconnection between host inflammation and SARS-CoV-2.
A novel in silico approach applied to drug screening has revealed three potential candidates that may interact with multiple proteins of SARS‐CoV‐2.
Researchers have developed a workflow to study the behaviour of C. elegans in a high-throughput screen to identify Parkinson's disease drugs.
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.